ZYVOX linezolid 200mg/100mL injection infusion bag

国家: 澳大利亚

语言: 英文

来源: Department of Health (Therapeutic Goods Administration)

现在购买

产品特点 产品特点 (SPC)
23-06-2022
公众评估报告 公众评估报告 (PAR)
13-05-2019

有效成分:

linezolid, Quantity: 2 mg/mL

可用日期:

Pfizer Australia Pty Ltd

药物剂型:

Injection, solution

组成:

Excipient Ingredients: hydrochloric acid; sodium citrate dihydrate; water for injections; glucose monohydrate; sodium hydroxide; citric acid

给药途径:

Intravenous

每包单位数:

1 bag, 10 bags

处方类型:

(S4) Prescription Only Medicine

疗效迹象:

Zyvox is indicated for the treatment of suspected or proven infections due to Gram positive organisms resistant to multiple classes of antibiotics, including methicillin resistant Staphylococcus species and vancomycin resistant Enterococcus species. Zyvox (linezolid) is active against Gram-positive bacteria only. Linezolid has no clinical activity against Gram-negative pathogens. Specific Gram-negative therapy is required if a concomitant Gram-negative pathogen is documented or suspected..

產品總結:

Visual Identification: A clear, colourless to yellow solution free from visible particulates.; Container Type: Bag; Container Material: PP; Container Life Time: 3 Years; Container Temperature: Store below 25 degrees Celsius; Container Closure: Neither child resistant closure nor restricted flow insert

授权状态:

Licence status A

授权日期:

2001-09-24

产品特点

                                Version: pfpzyvoa10622
Supersedes: pfpzyvoa10821
Page 1 of 26
AUSTRALIAN
PRODUCT
INFORMATION
–
ZYVOX
® (LINEZOLID)
1.
NAME OF THE MEDICINE
Linezolid.
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
TABLETS
Each Zyvox tablet contain 600 mg linezolid.
GRANULES FOR ORAL SUSPENSION
Following reconstitution with 123 mL of water, each mL contains 20 mg
of linezolid.
SOLUTION FOR INJECTION
Each 1 mL of Zyvox solution for injection (Zyvox injection) contains 2
mg of linezolid.
EXCIPIENT(S) WITH KNOWN EFFECT
GRANULES FOR ORAL SUSPENSION
Each mL contains 210.6 mg sucrose, 100 mg mannitol (E421) and 7 mg
aspartame (E951),
sodium as sodium citrate dihydrate (3 mg), sodium benzoate (2 mg) and
sodium chloride (2.7
mg). Fructose and sorbitol (E420) are present in mafco magna sweet (12
mg) and sweet-am
powder (6 mg).
SOLUTION FOR INJECTION
Each mL contains 50.24 mg glucose monohydrate and sodium as sodium
citrate dihydrate
(1.64 mg).
For the full list of excipients, see Section 6.1 List of excipients.
3.
PHARMACEUTICAL FORM
TABLETS
Zyvox 600 mg tablets are white to off-white coated tablet with
“ZYV” debossed on one side
and “600” debossed on the other.
GRANULES FOR ORAL SUSPENSION
Zyvox granules for oral suspension are white to yellow-orange and may
contain white to
yellow-orange-brown lumps. The constituted suspension is white to
yellow-orange and orange
flavoured.
SOLUTION FOR INJECTION
Zyvox injection is in an isotonic, clear, colourless to yellow
solution with pH between 4.4-5.2.
Version: pfpzyvoa10622
Supersedes: pfpzyvoa10821
Page 2 of 26
4.
CLINICAL PARTICULARS
4.1 THERAPEUTIC INDICATIONS
Zyvox is indicated for the treatment of suspected or proven infections
due to Gram positive
organisms
resistant
to
multiple
classes
of
antibiotics,
including
methicillin
resistant
_Staphylococcus_
species and vancomycin resistant
_Enterococcus_
species.
Zyvox is active against Gram-positive bacteria only. Zyvox has no
clinical activity against
Gram-negative pathogens. Specific Gram-negative therapy is required if
a concomitant Gra
                                
                                阅读完整的文件